{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:59:28Z","timestamp":1789397968267,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["1401-3-408-63299"],"award-info":[{"award-number":["1401-3-408-63299"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.anndiagpath.2023.152184","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T14:40:45Z","timestamp":1690382445000},"page":"152184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact"],"prefix":"10.1016","volume":"66","author":[{"given":"Ramtin","family":"Edjtemaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Nili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Jahanzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshteh","family":"Ameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorsa","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2023.152184_bb0005","article-title":"A review of the clinical characteristics and novel molecular subtypes of endometrioid ovarian cancer","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0010","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/PAT.0b013e328348a6e7","article-title":"Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis","volume":"43","author":"McCluggage","year":"2011","journal-title":"Pathology."},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-021-00804-1","article-title":"Ovarian endometrioid carcinoma and clear cell carcinoma: a 21-year retrospective study","volume":"14","author":"Zhou","year":"2021","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2012.04.021","article-title":"Clear cell carcinoma of the ovary: a review of the literature","volume":"126","author":"Del Carmen","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","article-title":"Clear cell renal cell carcinoma ontogeny and mechanisms of lethality","volume":"17","author":"Jonasch","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0030","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3389\/fgene.2019.00320","article-title":"Molecular mechanisms in clear cell renal cell carcinoma: role of miRNAs and hypermethylated miRNA genes in crucial oncogenic pathways and processes","volume":"10","author":"Braga","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0035","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/CCO.0000000000000873","article-title":"Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer)","volume":"34","author":"Gaye","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0040","article-title":"The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma","author":"Talia","year":"2022","journal-title":"RCPA."},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5858\/arpa.2012-0416-RA","article-title":"HER2\/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges","volume":"138","author":"Buza","year":"2014","journal-title":"Arch Pathol Lab"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0050","author":"College of American Pathologists"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0055","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/his.13704","article-title":"HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation","volume":"73","author":"Koopman","year":"2018","journal-title":"Histopathology."},{"issue":"5","key":"10.1016\/j.anndiagpath.2023.152184_bb0060","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5858\/arpa.2013-0566-CP","article-title":"Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast","volume":"138","author":"Fitzgibbons","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0065","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinucal Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0090-8258(92)90103-P","article-title":"HER-2\/neu expression: a major prognostic factor in endometrial cancer","volume":"47","author":"Hetzel","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000055404","article-title":"HER2 as a prognostic factor in breast cancer","volume":"61","author":"M\u00e9nard","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0080","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00384-006-0192-8","article-title":"HER-2\/neu overexpression is an independent prognostic factor in colorectal cancer","volume":"22","author":"Park","year":"2007","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0085","first-page":"198","article-title":"Prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer","volume":"17","author":"Sawada","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0090","article-title":"Practical updates and diagnostic challenges in endometrial carcinoma","author":"Turashvili","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0095","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study","volume":"159","author":"Erickson","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0110","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13000-016-0553-8","article-title":"Systematic assessment of HER2\/neu in gynecologic neoplasms, an institutional experience","volume":"11","author":"Woo","year":"2016","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-017-0304-9","article-title":"Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy","volume":"10","author":"Li","year":"2017","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0125","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/1078-0432.CCR-10-1688","article-title":"Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas","volume":"17","author":"Tan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/PGP.0b013e3182518557","article-title":"Clinicopathologic and immunohistochemical features of ovarian clear cell carcinomas in comparison with type I and type II tumors","volume":"31","author":"Zannoni","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0135","article-title":"Clear cell carcinoma of the endometrium: evaluation of prognostic parameters in 27 cases","volume":"5081","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0140","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/his.14419","article-title":"Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma","volume":"79","author":"Lin","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0145","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41379-021-00746-5","article-title":"Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study","volume":"34","author":"Buza","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0150","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP companion society session at the 2020 USCAP annual meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/PGP.0000000000000690","article-title":"Does specimen type have an impact on HER2 status in endometrial serous carcinoma? Discordant HER2 status of paired endometrial biopsy and hysterectomy specimens in the presence of frequent intratumoral heterogeneity","volume":"40","author":"Rottmann","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.humpath.2023.04.009","article-title":"Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma","volume":"137","author":"Sukov","year":"2023","journal-title":"Hum Pathol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154258","article-title":"The statuses of HER2 expression and mismatch repair in endometrial clear cell carcinoma","volume":"241","author":"Bayramoglu","year":"2023","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0170","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","article-title":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","volume":"35","author":"Ross","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0175","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3390\/cancers15051435","article-title":"HER2 amplification in p53-mutated endometrial carcinomas","volume":"15","author":"Balestra","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0180","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1186\/s12885-022-10478-7","article-title":"Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study","volume":"22","author":"Ghasemi","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.anndiagpath.2023.152184_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/1807929","article-title":"Epidemiology of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in solid tumors: a structured literature review","volume":"2020","author":"Lorenzi","year":"2020","journal-title":"J Oncol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913423000825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913423000825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:37:35Z","timestamp":1778798255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913423000825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":37,"alternative-id":["S1092913423000825"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2023.152184","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2023.152184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152184"}}